It is a clinical trial to study the effect of Murawwaquain in liver diseases patient

Effect of Murawwaquain on altered liver enzymes among patients of hepatobiliary diseases

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/011981

Enrollment

Registered

2018-02-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K709- Alcoholic liver disease, unspecified Health Condition 2: null- Altered Liver enzymes patient were enrolled

Interventions

Intervention1: Murawwaquain: Cichorium intybus and Solanum Nigrum is given in aqueous extract form 50ml each twive a day orally before food without water Control Intervention1: Not Applicant: Not Appl

Eligibility

Inclusion criteria

Inclusion criteria: In present study, Raised Serum Liver Transaminases(AST, ALT, Alkaline phosphatase), Raised serum Bilirubin level, Both gender,Age between 20-60years patients are included in trial.

Exclusion criteria

Exclusion criteria: patients of Age 60years, Pregnant and lactating mothers, Patient who fail to follow protocol, History of any systemic and metabolic diseases(Hypertension & Diabetes mellitus)are excluded.

Design outcomes

Primary

Measure	Time frame
Change in altered liver enzymesTimepoint: 3 weeks	—

Secondary

Measure	Time frame
Change in subjective parameterTimepoint: 3 weeks	—

Countries

India

Contacts

Public ContactFarooqui Shazia Parveen

National Institiute of Unani medicine

drmaquamri@gmail.com9341072974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026